Home · Health · Oct 16 archive
New Menopause Treatment Guidelines Offer Broader Options
· Confirmed
In Short: The new guidelines and approvals reflect a broader approach to treating menopause symptoms and other health issues, offering more personalized and effective options for patients.
The FDA has approved Brytly, a nonprescription eye drop solution containing apraclonidine, for treating eye redness caused by minor irritations. The product, manufactured by Alcon, is the first over-the-counter eye drop of its kind and is approved for use in adults and children aged 12 and older.
Patients are advised to remove contact lenses before using Brytly and wait at least 10 minutes after applying the drops before reinserting them.
For the first time since 2014, the American College of Obstetricians and Gynecologists (ACOG) has updated its guidelines for treating symptoms associated with menopause. The new guidelines highlight a broader range of options, including hormone therapy and nonhormonal treatments like Veozah and Lynkuet, which were approved in 2023 and 2025, respectively.
Catherine Cansino, MD, MPH, an obstetrician/gynecologist and co-author of the new guidance, emphasized the importance of individualized approaches to menopause treatment. 'What's changing is the breadth of options that we now have... And the benefit of that is that we are better equipped to be able to take an individualized approach for patients,' she said.
Robert Kauffman, MD, MSCP, another co-author of the guidelines, noted that hormone therapy is the best option for newly menopausal women within 10 years of their final menstrual period or before the age of 60.
The updated guidelines also address sleep disturbances, which affect an estimated 40% to 60% of menopausal women. A preliminary analysis of the OPTION-VMS real-world study showed that treatment with fezolinetant was associated with significant improvements in sleep outcomes as early as week 4.
Additionally, the FDA has approved a new drug targeting the mutations that drive more than 90% of pancreatic cancer cases, marking a significant advance for a disease with limited treatment options and a five-year survival rate of just 13%.
A compound produced in the body after eating pomegranates has shown promise in improving heart function by up to 80% in experimental models of a type of heart failure with limited treatment options.
In another development, Kaiser Permanente research found that a clinical pharmacist with diabetes management expertise can effectively move patients onto safer treatment regimens by discussing hypoglycemia and alternative options. When the study began, 74% of patients had treatment regimens that included medications that could increase their risk for hypoglycemia.
These advancements underscore the ongoing efforts to combat various health conditions and provide more effective treatment options for patients.
What this adds
The new guidelines and approvals reflect a broader approach to treating menopause symptoms and other health issues, offering more personalized and effective options for patients.
What's confirmed
- The FDA has approved Brytly, a nonprescription eye drop solution containing apraclonidine, for treating eye redness caused by minor irritations. The product, manufactured by Alcon, is the first over-the-counter eye drop of its kind and is approved for use in adults and children aged 12 and older.
- Patients are advised to remove contact lenses before using Brytly and wait at least 10 minutes after applying the drops before reinserting them.
- For the first time since 2014, the American College of Obstetricians and Gynecologists (ACOG) has updated its guidelines for treating symptoms associated with menopause. The new guidelines highlight a broader range of options, including hormone therapy and nonhormonal treatments like Veozah and Lynkuet, which were approved in 2023 and 2025, respectively.
- Catherine Cansino, MD, MPH, an obstetrician/gynecologist and co-author of the new guidance, emphasized the importance of individualized approaches to menopause treatment. 'What's changing is the breadth of options that we now have... And the benefit of that is that we are better equipped to be able to take an individualized approach for patients,' she said.
- Robert Kauffman, MD, MSCP, another co-author of the guidelines, noted that hormone therapy is the best option for newly menopausal women within 10 years of their final menstrual period or before the age of 60.
- The updated guidelines also address sleep disturbances, which affect an estimated 40% to 60% of menopausal women. A preliminary analysis of the OPTION-VMS real-world study showed that treatment with fezolinetant was associated with significant improvements in sleep outcomes as early as week 4.
- Additionally, the FDA has approved a new drug targeting the mutations that drive more than 90% of pancreatic cancer cases, marking a significant advance for a disease with limited treatment options and a five-year survival rate of just 13%.
- A compound produced in the body after eating pomegranates has shown promise in improving heart function by up to 80% in experimental models of a type of heart failure with limited treatment options.
- In another development, Kaiser Permanente research found that a clinical pharmacist with diabetes management expertise can effectively move patients onto safer treatment regimens by discussing hypoglycemia and alternative options. When the study began, 74% of patients had treatment regimens that included medications that could increase their risk for hypoglycemia.
- These advancements underscore the ongoing efforts to combat various health conditions and provide more effective treatment options for patients.
What's still developing
- The growing availability of biologic therapies such as anti-TNF, anti-interleukin-17 (anti-IL-17), and anti-IL-23, along with newer oral agents, is reshaping treatment goals in psoriasis.
- Holanda warned, however, that many “false failures” result from poor adherence, underdosing, incorrect dosing frequency, interruptions in dispensing, or an erroneous differential diagnosis.
- Gevalka, one of the approved medicines, is a targeted treatment for adults with advanced non-small cell lung cancer (NSCLC) that is positive for the ALK marker.
- Experts say we need more options for treating ADHD, and a 2025 study suggests one option might already be stocked at the chemist.
- "Our research indicates that, due to its existing approval and safety profile, amlodipine could be rapidly redeployed as a treatment option for ADHD, potentially providing relief to patients sooner than developing new medications."
- The FDA has approved new first-line zanidatamab-based treatment options for certain people with HER2-positive advanced stomach, gastroesophageal junction, and esophageal cancers.
- Testing a tumor for HER2 can help the cancer care team determine whether a HER2-targeted treatment may be appropriate.
- Since joining Mayo, Dr. Oskarsson has helped translate advances in ALS genetics into treatment research, contributing to the first approved treatment of genetic ALS.
- "It speaks to the power of science and how far genetically targeted treatments have come."
- Always take Tukysa exactly as your healthcare provider tells you to and continue taking it alongside your other prescribed maintenance treatments.
- " HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer."
- It’s a moment that marks the beginning of a new era of treatment for pancreatic cancer, said PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc.